Use este identificador para citar ou linkar para este item:
https://www.arca.fiocruz.br/handle/icict/7457
SERUM SOLUBLE MARKERS IN THE EVALUATION OF TREATMENT IN HUMAN VISCERAL LEISHMANIASIS
Antígenos CD4/sangue
Antígenos CD8/sangue
Antimônio/uso terapêutico
Biopterina/análogos & derivados
Biopterina/sangue
Humanos
Molécula 1 de Adesão Intercelular/sangue
Leishmaniose Visceral/quimioterapia
Neopterina
Receptores de Interleucina-2/análise
Autor(es)
Afiliação
Fundação Oswaldo Cruz. Centro de Pesquisa Gonçalo Moniz. Laboratório Integrado de Microbiologia e Imunorregulação. Salvador, BA, Brasil
Universidade Federal da Bahia. Serviço de Imunologia. Hospital Universitário Prof. Edgard Santos. Salvador, BA, Brasil
Universidade Federal da Bahia. Serviço de Imunologia. Hospital Universitário Prof. Edgard Santos. Salvador, BA, Brasil
Fundação Oswaldo Cruz. Centro de Pesquisa Gonçalo Moniz. Laboratório Integrado de Microbiologia e Imunorregulação. Salvador, BA, Brasil
Universidade Federal da Bahia. Serviço de Imunologia. Hospital Universitário Prof. Edgard Santos. Salvador, BA, Brasil
Universidade Federal da Bahia. Serviço de Imunologia. Hospital Universitário Prof. Edgard Santos. Salvador, BA, Brasil
Fundação Oswaldo Cruz. Centro de Pesquisa Gonçalo Moniz. Laboratório Integrado de Microbiologia e Imunorregulação. Salvador, BA, Brasil
Resumo em Inglês
Visceral leishmaniasis (VL) has a fatal course if not properly treated. Recovery from VL is linked
to cellular immune response. Unresponsiveness to antimonial therapy reinforces the importance of
determining parameters for treatment assessment. We analysed the pre- and post-treatment serum
levels of soluble CD4 (sCD4), sCD8, sIL-2R, soluble intercellular adhesion molecule- I (sICAM- 1)
and neopterin in groups of VL patients either responsive or not to standard antimonial therapy.
Pretreatment serum levels of all markers except for sICAM-1 were significantly higher in VL
patients than in healthy subjects from the same area (P < 0-05). sICAM-1 levels were similar in
healthy controls and in VL patients refractory to antimonial therapy (P= 0 25), but significantly
higher in patients responsive to treatment (P = 0-02). The comparison of pre- and post-treatment
concentrations showed that all markers, except sCD4 and sICAM-1, presented a significant fall
(P < 0 05) in patients responsive to antimonial therapy. However, only neopterin presented with
levels compatible with those of healthy subjects at the end of treatment (P = 0 30). In refractory
patients sICAM-1 presented with post-treatment levels significantly higher than the pretreatment
determinations (P=0003), while sCD4 experienced a significant drop (P=0001). All markers
displayed clearly distinct behaviour according to the patient's response to therapy. This makes all
soluble molecules studied suitable for use as indicators of antimonial therapy response. Additionally
the comparison of pretreatment levels of the markers between responders and refractory
patients to antimonial therapy showed that serum concentrations of sIL-2R and sICAM-1
significantly differed among these two groups (P= 0 02 in each case), suggesting that they may
be used in future as predictors of antimonial therapy response.
DeCS
Leishmaniose Visceral/imunologiaAntígenos CD4/sangue
Antígenos CD8/sangue
Antimônio/uso terapêutico
Biopterina/análogos & derivados
Biopterina/sangue
Humanos
Molécula 1 de Adesão Intercelular/sangue
Leishmaniose Visceral/quimioterapia
Neopterina
Receptores de Interleucina-2/análise
Compartilhar